Aduro Biotech Presents Preclinical Data On Enhanced Anti-Tumor Activity With Small-Molecule Immunotherapy Program

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. presented preclinical data at the Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, Maryland on Saturday, November 9th on the development of synthetic derivatives of the naturally-occurring small molecules that stimulate the STING (STimulator of INterferon Genes) receptor. The data, which highlighted the significantly increased anti-tumor activity of the company’s proprietary derivative molecules, were presented by Thomas W. Dubensky, Jr., Ph.D., chief scientific officer of Aduro.

Help employers find you! Check out all the jobs and post your resume.